Researchers identify factors responsible for chronic nature of autoimmune disease

January 4, 2017, Massachusetts Eye and Ear Infirmary

Researchers from Schepens Eye Research Institute of Massachusetts Eye and Ear have uncovered two factors responsible for the chronic, lifelong nature of autoimmune disorders, which tend to "flare up" intermittently in affected patients. These two factors are cell-signaling proteins called cytokines—specifically Interleukin-7 and -15 (IL-7 and IL-15)—that are secreted by cells of the immune system and help modulate memory Th17 cells, a subset of T cells which are known to contribute to autoimmune disorders. Until now, it was unclear how Th17 cells maintained memory; the study results show that IL-7 and IL-15 signal the Th17 cells to chronically reside in the body. These findings, published online in the Journal of Autoimmunity, may lead to the development of new therapies to address a variety of chronic autoimmune disorders.

"We wanted to know the precise factors that maintain memory in Th17 so that we can better understand what is causing chronic ," said senior author Reza Dana, M.D., M.Sc., MPH, Director of the Cornea and Refractive Surgery Service at Mass. Eye and Ear and the Claes H. Dohlman Professor of Ophthalmology at Harvard Medical School. "By selectively targeting the production and expression of IL-7 and IL-15, we may be able to prevent the development of chronic autoimmune disorders."

Affecting up to 50 million Americans, autoimmune disorders develop when the body's immune system attacks its own healthy tissue. Many autoimmune disorders are chronic, and patients may experience "flare-ups," in which symptoms worsen temporarily and then enter a period of remission.

Previous research studies have linked Th17 cells to a variety of autoimmune disorders, including multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and chronic inflammatory eye disorders such as uveitis and . When Th17 cells are activated, a subset of them become memory cells, causing them to reside in the body for long periods of time. These memory Th17 cells can become reactivated and cause flare-ups of the . However, the underlying mechanisms that promote the maintenance of Th17 memory were previously unknown.

Using a mouse model for dry , an autoimmune condition affecting the surface of the eye, the study authors set out to determine what molecular factors are critical for the maintenance of Th17 memory. They identified IL-7 and -15 as playing a crucial role in the survival and homeostatic proliferation of memory Th17 cells, and when they neutralized IL-7 and IL-15, they saw a substantial reduction of memory Th17 cells.

While further studies are needed to determine ways to block these factors, the findings suggest that targeting IL-7 and IL-15 in order to remove the memory Th17 cells may be an effective treatment strategy for autoimmune diseases.

"In the case of dry eye disease, many of the treatments are showing limited efficacy in patients that do not have a highly inflamed eye," said Dr. Dana. "Targeting the chronic, immune nature of may be a better strategy for controlling these conditions."

Explore further: Researchers discover how vascular disease activates autoimmune disorders

More information: Yihe Chen et al, Interleukin-7 and -15 maintain pathogenic memory Th17 cells in autoimmunity, Journal of Autoimmunity (2016). DOI: 10.1016/j.jaut.2016.11.003

Related Stories

Researchers discover how vascular disease activates autoimmune disorders

January 9, 2014
The hardening of the arteries, also called atherosclerosis, that can lead to heart attack or stroke. has also been linked to autoimmune disorders. It has not been clear why these diseases are related, but a study published ...

Will blocking IL-17A help treat kidney disease?

January 22, 2016
Many different diseases and insults can injure kidneys, resulting in kidney failure. Some autoimmune diseases damage glomeruli (the 'filtering units' of the kidney), while problems with the tubules (for example, impaired ...

New class of molecules play key role in influencing the immune system

August 24, 2016
In a study published online this week in Science Translational Medicine, investigators from Brigham and Women's Hospital and the Santa Lucia Foundation in Rome report that resolvins and maresins, molecules produced in the ...

Tpl2 enzyme may be target for treating autoimmune diseases

May 22, 2015
New research at the University of Georgia has found that the presence of Tpl2—an enzyme that regulates inflammation—controls the activation of T cells during colitis, an autoimmune disease that occurs when the inner lining ...

DNA-modulating drug attenuates lung inflammation in mice

July 21, 2016
Patients with cystic fibrosis (CF) suffer from chronic respiratory infections, primarily caused by Pseudomonas aeruginosa, which lead to airway inflammation and damage. Several recent studies have suggested that a specific ...

Recommended for you

Improving vaccines for the elderly by blocking inflammation

January 22, 2018
By identifying why skin immunity declines in old age, a UCL-led research team has found that an anti-inflammatory pill could help make vaccines more effective for elderly people.

Novel genomic tools provide new insight into human immune system

January 19, 2018
When the body is under attack from pathogens, the immune system marshals a diverse collection of immune cells to work together in a tightly orchestrated process and defend the host against the intruders. For many decades, ...

Genomics reveals key macrophages' involvement in systemic sclerosis

January 18, 2018
A new international study has made an important discovery about the key role of macrophages, a type of immune cell, in systemic sclerosis (SSc), a chronic autoimmune disease which currently has no cure.

First vaccine developed against grass pollen allergy

January 18, 2018
Around 400 million people worldwide suffer in some form or other from a grass pollen allergy (rhinitis), with the usual symptoms of runny nose, cough and severe breathing problems. In collaboration with the Viennese firm ...

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.